Cure8

Why This Matters

This study suggests that people with PSC-IBD may respond differently to some biologic treatments: infliximab and vedolizumab had similar early effectiveness versus IBD alone, but ustekinumab showed a lower early response in PSC-IBD. That could influence treatment discussions for patients with concurrent PSC.

Who Should Pay Attention

Patients with IBD plus primary sclerosing cholangitis, clinicians prescribing biologics, researchers in IBD therapeutics.

Study Snapshot

Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract

What To Know

The researchers matched 46 PSC-IBD patients to 46 IBD controls and analyzed 136 treatment courses with a median follow-up of roughly 3–5 years. The primary outcome was clinical response at 20 weeks (remission by partial Mayo or Harvey-Bradshaw Index).

Secondary outcomes included treatment persistence at 12 months, endoscopic response, faecal calprotectin changes, concomitant meds, and safety.

Key finding reported: infliximab and vedolizumab showed similar early clinical response rates in PSC-IBD versus IBD-alone patients; ustekinumab had a significantly lower 20-week clinical response rate in PSC-IBD (42.9%) than in IBD-alone (76.9%).

Treatment persistence differences were not statistically significant but numerically lower for ustekinumab in PSC-IBD. What this is not This abstract summarizes a single-center, observational case-control analysis; it does not establish causation or provide guidance on choosing therapy for individual patients.

It does not report long-term comparative effectiveness beyond the measures described.

Keep In Mind

Single-center, propensity-matched observational study summarized in the journal abstract. Results reflect early (20-week) clinical response and real-world practice; they do not prove superiority or infer long-term outcomes. Sample sizes within drug subgroups are modest.

Source Details

Review the original publication for the complete reporting, methods, and context.

Read Original Source
Research paper Evidence type derived from source or registry metadata.
PublicationGastroenterology report
AuthorsRobert Tosse, Martin Maibier, Andreas Fischer +5 more
InstitutionDepartment of Hepatology and Gastroenterology, Charité-Universitätsmedizin Berlin, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin 13353, Germany.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedJul 30, 2026, 12:00 AM
Content availableJournal abstract

Conflict statement: J.W. has received honoraria for consulting for Alfasigma and Janssen-Cilag. F.T.’s lab has received research grants (funding to the institution) from AstraZeneca, MSD, Gilead Sciences, Inc., AgomAb Therapeutics NV. F.T. has received honoraria for consulting or lectures from Gilead, AbbVie Inc., Dr Falk Pharma GmbH, AstraZeneca, Boehringer Ingelheim, Mirum, Madrigal, MSD, GSK, Ipsen, Pfizer, Novartis, Novo Nordisk, Sanofi. All other authors declare no conflict of interest.

This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.

Related Reading

Browse latest news →